ALPINE GROUP PARTNERS, LLC. for ULTRAGENYX PHARMACEUTICAL INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEENAN AUSTIN REED | — |
| ERIN MENDELSOHN | — |
| SHAYNE WOODS | — |
Government Issues GOV
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEENAN AUSTIN REED | — |
| ERIN MENDELSOHN | — |
| SHAYNE WOODS | — |
Medical/Disease Research/Clinical Labs MED
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEENAN AUSTIN REED | — |
| ERIN MENDELSOHN | — |
| SHAYNE WOODS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.